Canada Markets closed

ChemoCentryx, Inc. (CCXI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
51.660.00 (0.00%)
At close: 04:00PM EDT
51.61 -0.05 (-0.10%)
After hours: 07:54PM EDT

ChemoCentryx, Inc.

835 Industrial Avenue
Suite 600
San Carlos, CA 94070
United States
650 210 2900
https://www.chemocentryx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees178

Key Executives

NameTitlePayExercisedYear Born
Dr. Thomas J. Schall Ph.D.Founder, Pres, CEO & Chairman1.21M2.58M1959
Ms. Susan M. KanayaExec. VP, Chief Financial & Admin. Officer, Sec. and Director845.04kN/A1963
Mr. Tausif ButtExec. VP & COO1.01MN/A1966
Dr. Rita I. Jain M.D.Exec. VP, Chief Medical Officer & Exec. Employee Director670.7kN/A1963
Dr. Markus J. Cappel Ph.D.Chief Bus. Officer & Treasurer643.58k1.13M1961
Ms. Yi Ching YauSr. VP of Fin. & Principal Accounting OfficerN/AN/A1976
Mr. William S. SlatteryVP of Investor Relations & Corp. CommunicationsN/AN/AN/A
Ms. Kari E. LeetchSr. VP of HRN/AN/AN/A
Dr. Sangita Ghosh Ph.D.Sr. VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Corporate Governance

ChemoCentryx, Inc.’s ISS Governance QualityScore as of September 28, 2022 is 6. The pillar scores are Audit: 3; Board: 8; Shareholder Rights: 5; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.